Drug Trial Radar · NCT05712356
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
May 13, 2023
Primary completion
Apr 5, 2026
Study completion Apr 5, 2026
Sponsor
- Lead sponsor
- Lisata Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untreated cholangiocarcinoma or those that have progressed after first-line treatment for cholangiocarcinoma. The main questions it aims to answer are: * is the new drug plus standard treatment safe and tolerable * is the new drug plus standard treatment more effective than standard treatment
Conditions
- Cholangiocarcinoma
- Gallbladder Cancer
- Gallbladder Carcinoma
- Intrahepatic Cholangiocarcinoma
- Extrahepatic Cholangiocarcinoma
- Bile Duct Cancer
- Gall Bladder Cancer
- Gall Bladder Carcinoma
Interventions
certepetideDrug
LSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given
DurvalumabDrug
1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles
CisplatinDrug
cisplatin 25 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
GemcitabineDrug
gemcitabine 1000 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
FOLFOX regimenDrug
The following will be given every 14 days: * oxaliplatin 85 mg/m² and l-folinic acid 200 mg/m² or d,l-folinic acid 400 mg/m² concurrently, as a 2-hour IV infusion * fluorouracil (5-FU) 400 mg/m² will be given as an IV bolus over 5 minutes * fluorouracil (5-FU) 2400 mg/m² will be administered over 46 hours (via home-infusion pump)
PlaceboDrug
Placebo given as a slow IV push over 1 minute when standard treatment(s) are given
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Experiencing Any Adverse EventTime frame: From time of consent until 30 days after treatment discontinuation, up to 18 months
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
Mayo Clinic Arizona
Phoenix, Arizona
University of Arizona Cancer Center
Tucson, Arizona
Moffitt Cancer Center
Tampa, Florida
Alliance for Multispecialty Research
Merriam, Kansas
University of Kansas Cancer Center
Westwood, Kansas
University of Kentucky Medical Center
Lexington, Kentucky
Norton Cancer Institute, Downtown
Louisville, Kentucky
Norton Cancer Institute, Audubon
Louisville, Kentucky
Mayo Clinic Rochester
Rochester, Minnesota
Northwell Health - Zuckerberg Cancer Center
Lake Success, New York
Stony Brook Cancer Center
Stony Brook, New York
FirstHealth of the Carolinas, Inc.
Pinehurst, North Carolina
Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center
Cincinnati, Ohio
Spartanburg Medical Center
Spartanburg, South Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Inova Schar Cancer Institute
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.